Levi & Korsinsky Files Class Action Lawsuit Against Savara Inc. for Investor Recovery

Class Action Lawsuit Against Savara Inc. (SVRA)

In a significant legal move, Levi & Korsinsky, LLP has announced a class action lawsuit against Savara Inc. (NASDAQ: SVRA), focusing on the recovery of losses incurred by investors. This lawsuit is particularly aimed at those who believe they have been adversely affected by alleged securities fraud during the period from March 4, 2024, to May 23, 2025.

Defining the Class Action

This class action lawsuit seeks to represent all investors who purchased or otherwise acquired Savara Inc.'s securities within the specified timeframe. As outlined by Levi & Korsinsky, the case alleges a series of misleading statements made by the company regarding their product, MOLBREEVI, a treatment for pulmonary alveolar proteinosis. The complaint suggests that the company failed to disclose key information related to MOLBREEVI's chemistry, manufacturing, and controls, which essentially misled investors about the likelihood of obtaining FDA approval for the treatment.

Allegations of Fraud

The allegations state that Savara Inc.'s public statements contained material misrepresentations that led investors to believe in the company's operational integrity and regulatory standing. Specifically, the lawsuit claims that:
1. The defendants did not provide sufficient details about MOLBREEVI’s production processes, creating doubts about its safety and efficacy.
2. The FDA was not likely to approve the BLA (Biologics License Application) for MOLBREEVI in its current form.
3. Misleading statements led investors to wrongly ascertain that Savara would meet projected timelines for regulatory approval.
4. The potential delay in FDA approval raised concerns about the company's future capital requirements.

This confluence of factors contributed to a decline in investor confidence when the true state of affairs became apparent.

Next Steps for Investors

Investors who believe they suffered losses due to Savara Inc.'s alleged misstatements are encouraged to take action. The deadline to request the court to appoint a lead plaintiff is set for November 7, 2025. Importantly, investors interested in participating in this litigation can do so without incurring out-of-pocket costs, as the firm operates on a contingency basis.

Levi & Korsinsky’s Credentials

Levi & Korsinsky has built a robust reputation over the past two decades, having secured hundreds of millions of dollars for shareholders through successful litigation in complex securities cases. With a team of over 70 legal professionals, the firm is dedicated to representing aggrieved investors and has consistently been ranked among the top securities litigation firms in the United States, according to ISS Securities Class Action Services.

If you are an investor in Savara Inc. who has been impacted by these developments, consider reaching out to Levi & Korsinsky for assistance. They can be contacted at:

- Email: [email protected]
- Phone: (212) 363-7500

The firm is prepared to guide you through the legal process and help you pursue rightful compensation for any financial damages incurred due to the alleged actions of Savara Inc.